Elizabeth Kulikova

Dr. Elizabeth Kulikova

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
NGNataliya Gorinski
Nataliya Gorinski
MBMonika Bijata
Monika Bijata
SPSonal Prasad
Sonal Prasad
AWAlexander Wirth
Alexander Wirth
DGDalia Abdel Galil
Dalia Abdel Galil
EPEvgeni Ponimaskin
Evgeni Ponimaskin
The serotonergic system and in particular serotonin 1A receptor (5-HT1AR) are implicated in major depressive disorder (MDD). Here we demonstrated that 5-HT1AR is palmitoylated in human and rodent brains, and identified ZDHHC21 as a major palmitoyl acyltransferase, whose depletion reduced palmitoylation and consequently signaling functions of 5-HT1AR. Two rodent models for depression-like behavior show reduced brain ZDHHC21 expression and attenuated 5-HT1AR palmitoylation. Moreover, selective knock-down of ZDHHC21 in the murine forebrain induced depression-like behavior. We also identified the microRNA miR-30e as a negative regulator of Zdhhc21 expression. Through analysis of the post-mortem brain samples in individuals with MDD that died by suicide we find that miR-30e expression is increased, while ZDHHC21 expression, as well as palmitoylation of 5-HT1AR, are reduced within the prefrontal cortex. Our study suggests that downregulation of 5-HT1AR palmitoylation is a mechanism involved in depression, making the restoration of 5-HT1AR palmitoylation a promising clinical strategy for the treatment of MDD.

1 February 2017 in Neuroscience Letters
Verified
Journal Article
Closed access
EKElizabeth Kulikova
Elizabeth Kulikova
VKV.A. Kulikov
V.A. Kulikov
NSN.A. Sinyakova
N.A. Sinyakova
AKA.V. Kulikov
A.V. Kulikov
NPN.K Popova
N.K Popova

1 December 2018 in Neuroscience
Verified
Journal Article
Closed access
EKElizabeth Kulikova
Elizabeth Kulikova
NKN.V. Khotskin
N.V. Khotskin
NIN.B. Illarionova
N.B. Illarionova
ISI.E. Sorokin
I.E. Sorokin
EBE.Y. Bazhenova
E.Y. Bazhenova
AKA.V. Kulikov
A.V. Kulikov

30 August 2017 in Current Protein & Peptide Science
Verified
Journal Article
Closed access
PDF file
EKElizabeth Kulikova
Elizabeth Kulikova
AKAlexander Kulikov
Alexander Kulikov
Striatal-enriched tyrosine protein phosphatase (STEP) is expressed mainly in the brain. Its dysregulation is associated with Alzheimer’s and Huntington’s diseases, schizophrenia, fragile X syndrome, drug abuse and stroke/ischemia. However, an association between STEP and depressive disorders is still obscure. The review discusses the theoretical foundations and experimental facts concerning possible relationship between STEP dysregulation and depression risk. STEP dephosphorylates and inactivates several key neuronal signaling proteins such as extracellular signal-regulating kinase 1 and 2 (ERK1/2), stress activated protein kinases p38, the Src family tyrosine kinases Fyn, Pyk2, NMDA and AMPA glutamate receptors. The inactivation of these proteins decreases the expression of brain derived neurotrophic factor (BDNF) necessary for neurogenesis and neuronal survival. The deficit of BDNF results in progressive degeneration of neurons in the hippocampus and cortex and increases depression risk. At the same time, a STEP inhibitor, 8-(trifluoromethyl)-1,2,3,4,5-benzopentathiepin-6-amine hydrochloride (TC-2153), increases BDNF expression in the hippocampus and attenuated the depressivelike behavior in mice. Thus, STEP is involved in the mechanism of depressive disorders and it is a promising molecular target for atypical antidepressant drugs of new generation.

29 January 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
VMVitalii Moskaliuk
Vitalii Moskaliuk
RKRimma V. Kozhemyakina
Rimma V. Kozhemyakina
DBDarya Bazovkina
Darya Bazovkina
ETElena Terenina
Elena Terenina
TKTATYANA M KHOMENKO
TATYANA M KHOMENKO
EKElizabeth Kulikova
Elizabeth Kulikova
Striatal-enriched protein tyrosine phosphatase (STEP) is a signal transduction protein involved in the pathogenesis of neuropathologies. A STEP inhibitor (TC-2153) has antipsychotic and antidepressant effects. Here, we evaluated the role of STEP in fear-induced aggression using Norway rats selectively bred for 90 generations for either high aggression toward humans (aggressive rats) or its absence (tame rats). We studied the effects of acute administration of TC-2153 on behavior and STEP expression in the brain of these animals and the influence of chronic treatment with TC-2153 on the behavior and STEP expression in aggressive rats in comparison with classic antidepressant fluoxetine, which is known to exert antiaggressive action. Acute TC-2153 administration decreased the aggressive reaction to humans in aggressive rats, while having no impact on the friendly behavior of tame rats. Moreover, in the elevated plus-maze test, the drug had an anxiolytic effect on both aggressive and tame rats. Aggressive rats demonstrated elevated levels of a STEP isoform (STEP46) as compared to tame animals, whereas acute TC-2153 administration significantly reduced STEP46 protein concentration in the brain of aggressive rats. Chronic treatment of aggressive rats with either TC-2153 or fluoxetine attenuated fear-induced aggression. Chronic administration of fluoxetine enhanced the exploratory activity in the elevated plus-maze test and decreased the STEP46 protein level in aggressive rats' hippocampus, whereas chronic TC-2153 administration did not affect these parameters. Thus, STEP46 can play an important role in the mechanisms of aggression and may mediate antiaggressive effects of TC-2153 and fluoxetine.

1 September 2005 in Kinetics and Catalysis
Verified
Journal Article
Closed access
PDF file
AAA. V. Abramova
A. V. Abramova
ESE. V. Slivinskii
E. V. Slivinskii
YGYu. Ya. Goldfarb
Yu. Ya. Goldfarb
APAlexander Panin
Alexander Panin
EKElizabeth Kulikova
Elizabeth Kulikova
GKG. A. Kliger
G. A. Kliger